8-K
filed March 6, 2026, 6:59 PM ET
ticker OSTX
CIK 0001795091
debt
confidence high
sentiment negative
materiality 0.65
OS Therapies Inc (OSTX): debt financing — OS Therapies raises $2M via 10% OID convertible notes and warrants; $2.2M principal
OS Therapies Inc
- Gross proceeds $2M; notes carry 4% interest, mature March 4, 2027.
- Warrants to purchase up to 1,666,667 shares at $1.40, 5-year term; 100% warrant coverage.
- Conversion: mandatory upon qualified offering ≥$2.5M; voluntary at 90% of 10-day VWAP.
- Proceeds to fund clinical trials, R&D, and working capital.
- 19.99% issuance cap without stockholder approval; resale registration to be filed within 30 days.
Key facts
Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
OS Therapies Inc incurred convertible notes of $2,200,000 at 4% per annum maturing March 4, 2027.
- Instrument
- convertible notes
- Principal
- $2,200,000
- Rate
- 4% per annum
- Maturity
- March 4, 2027
- Event
- incurrence
Exact text from the filing
Pursuant to the Purchase Agreement, the Company issued to the Purchasers (i) Notes in an aggregate principal amount of $2,200,000 and (ii) Warrants to purchase up to 1,666,667 shares of the Company’s common stock (the “Warrant Shares”), for aggregate gross proceeds of $2,000,000, before deducting placement agent fees and other Private Placement expenses.
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
OS Therapies Inc issued up to 1,666,667 shares of warrant to accredited investors for aggregate gross proceeds of $2,000,000.
- Security
- warrant
- Shares
- up to 1,666,667 shares
- Purchaser
- accredited investors
- Consideration
- aggregate gross proceeds of $2,000,000
Exact text from the filing
Warrants to purchase up to 1,666,667 shares of the Company’s common stock (the “Warrant Shares”), for aggregate gross proceeds of $2,000,000
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
OS Therapies Inc issued convertible note to accredited investors for aggregate gross proceeds of $2,000,000.
- Security
- convertible note
- Purchaser
- accredited investors
- Consideration
- aggregate gross proceeds of $2,000,000
Exact text from the filing
principal amount of $2,200,000 and (ii) Warrants to purchase up to 1,666,667 shares of the Company’s common stock (the “Warrant Shares”), for aggregate gross proceeds of $2,000,000, before deducting placement agent fees and other Private Placement expenses. The Notes were sold at a 10% original issue discount, such that for each $100,000 invested by a
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
OS Therapies Inc entered into Purchase Agreement with certain accredited investors valued at $2,200,000 aggregate principal amount of Notes and $2,000,000 aggregate gross proceeds (effective 2026-03-04).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain accredited investors
- Value
- $2,200,000 aggregate principal amount of Notes and $2,000,000 aggregate gross proceeds
- Effective
- 2026-03-04
Exact text from the filing
On March 4, 2026, OS Therapies Incorporated (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors (collectively, the "Purchasers"), pursuant to which the Company agreed to issue and sell to the Purchasers, in a private placement (the "Private Placement"), (i) 10.0% original issue discount unsecured convertible promissory notes (the "Notes") and (ii) warrants to purchase shares of the Company's common stock (the "Warrants" and, together with the Notes, the "Securities").
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.